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Background: Chronic obstructive pulmonary disease (COPD) often coexists with heart failure (HF), and is
considered tobeassociatedwithadverseoutcomes inHFpatients.However, the featuresof cardiovascular
function and the detailed all-cause mortality of HF with COPD remain unclear.
Methods and results: Consecutive 378 patients admitted for HF who underwent spirometry were divided
into three groups: HF without COPD (non-COPD group, n=272), HF with mild COPD (GOLD I group,
n=82), and HF with moderate COPD (GOLD II group, n=24). The GOLD II group, as compared to non-
COPD group, had (1) higher troponin T (p=0.009); (2) greater cardio-ankle vascular index (p=0.032);
and (3) similar cardiac systolic and diastolic function of the right and left ventricle. In addition, rates
of cardiac (p=0.049), non-cardiac (p=0.001), and all-cause mortality (p=0.002) were higher in GOLD IIroponin T
rognosis
group than in non-COPD and GOLD I groups. Importantly, in the Cox proportional hazard analyses, the
GOLD stage II was an independent predictor of cardiac (p=0.038), non-cardiac (p=0.036), and all-cause
mortality (p=0.015) in HF patients.
Conclusions:HFpatientswith coexistentmoderate COPD (GOLD stage II) have greatermyocardial damage,
greater arterial stiffness, and higher cardiac and non-cardiac mortality.
© 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.ntroduction
Chronic obstructive pulmonary disease (COPD) causes systemic
nﬂammation and is frequently associated with cardiovascular dis-
ases [1]. COPD and heart failure (HF) often mutually coexist in
linical practice [2–4]. It has been reported that COPD is associated
ith adverse clinical outcomes inHFpatients [5–8], but COPD is not
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914-5087/© 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights rean independent predictor of HF [9,10]. In HF patients, right ventri-
cular systolic function [11,12], pulmonary atrial pressure [12,13],
myocardial damage [14], signal averaged electrocardiogram (ECG)
as arrhythmia substrate [15], endothelial function [16], and arterial
stiffness [17] are the reported predictors of cardiac events.
However, the features of HF coexistent with COPD from the
viewpoint of comprehensive cardiovascular function and the
impact of COPD on detailed all-cause mortality in HF remain
unclear. The aims of the present study were to investigate (1) clin-
ical features; (2) cardiac function, including right heart function,
myocardial damage, and arrhythmia substrate; (3) vascular func-
tion including endothelial function and arterial stiffness; and (4)
prognosis, including not only cardiac events but also non-cardiac
events in HF patients with or without COPD.
served.
of Card
M
S
c
u
M
s
[
b
o
a
i
f
T
W
t
n
r
t
g
a
s
w
f
A
o
a
a
k
r
b
w
i
a
f
f
i
g
b
d
h
t
t
h
a
C
P
(
r
c
F
C
r
o
5
(
R
(A. Yoshihisa et al. / Journal
ethods
ubjects and study protocol
This was a prospective observational study which enrolled 388
onsecutive symptomatic HF patients who were hospitalized and
nderwent respiratory function test (spirometry) at Fukushima
edical University between 2009 and 2012. The diagnosis of
ymptomatic HF was deﬁned based on the Framingham criteria
18]. Patients with acute coronary syndrome, pulmonary throm-
oembolism, primary pulmonary hypertension, and past history
f asthma were excluded. The presence of COPD was deﬁned
s forced expiratory volume in 1 s (FEV1)/forced vital capac-
ty (FVC) <70% by spirometry according to the Global Initiative
or Chronic Obstructive Lung Disease (GOLD) and the American
horacic Society/European Respiratory Society guidelines [19,20].
e performed several examinations such as general laboratory
ests, ﬂow-mediated dilatation, cardio-ankle vascular index, sig-
al averaged ECG, and echocardiography in patients who were in a
elatively stable phase (before discharge), and compared parame-
ers among three groups based on spirometric ﬁndings (non-COPD
roup,GOLD I group, andGOLD II group). Hypertensionwasdeﬁned
s the recent use of antihypertensive drugs, or systolic blood pres-
ure ≥140mmHg and/or a diastolic pressure ≥90mmHg. Diabetes
as deﬁned as the recent use of insulin or antidiabetic drugs, a
asting blood glucose value of ≥126mg/dl, and/or a hemoglobin
1c value of ≥6.5%. Dyslipidemia was deﬁned as the recent use
f cholesterol-lowering drugs, a triglyceride value of ≥150mg/dl,
low-density lipoprotein cholesterol value of ≥140mg/dl, and/or
high-density lipoprotein cholesterol value of <40mg/dl. Chronic
idney disease was deﬁned as an estimated glomerular ﬁltration
ate (GFR) <60ml/min/1.73 cm2 [21]. Estimated GFRwasmeasured
y the Modiﬁcation of Diet in Renal Disease formula [21]. Anemia
as deﬁned as hemoglobin of <12.0 g/dl in females and <13.0 g/dl
n males [4]. A smoker was deﬁned as a person who had smoked
ny cigarettes in the past three months. Patients were followed up
or cardiac events (including cardiac death and/or progressiveheart
ailure), non-cardiac death, and all-cause mortality. Cardiac death
ncluded death due to ventricular ﬁbrillation or worsening HF. Pro-
ressive HF was deﬁned as re-hospitalization due to worsening HF
ased on the Framingham criteria [18]. Non-cardiac death included
eath due to respiratory failure, infection, sepsis, cancer, digestive
emorrhage, etc. Status and dates of deaths were obtained from
he patients’ medical records. If these data were unavailable, sta-
us was ascertained by a telephone call to the patient’s referring
ospital physician. Written informed consent was obtained from
ll study subjects. The study protocol was approved by the Ethical
ommittee of Fukushima Medical University.
ulmonary function test
Pulmonary function test was performed using a spirometer
CHESTAC-8900, Chest, Tokyo, Japan) when patients were in a
elatively stable phase, or during an euvolumic phase before dis-
harge. Spirometry was deﬁned by standard indices: FEV1, FVC,
EV1/FVC, vital capacity, %vital capacity, and peak expiratory ﬂow.
OPD (obstructive disorder) was deﬁned by a reduced FEV1/FVC
atio of <70% [19,20]. COPDwas graded as stage I (mild: FEV1 ≥80%
f expected for age and gender corresponded), stage II (moderate:
0%<FEV1 ≤80%), stage III (severe: 30%<FEV1 ≤50%), and stage IV
very severe: FEV1 <30%) as demonstrated in theGOLDcriteria [19].
estrictive disorder was characterized by reduced lung volumes
%vital capacity <80%).iology 64 (2014) 256–264 257
Flow-mediated dilatation
Endothelial function was evaluated blindly by means of ﬂow-
mediated dilatation [22]. After fasting overnight, patients were
required to lie at rest for at least 15min, and ﬂow-mediated dilata-
tion was assessed in the right arm in a supine position in a quiet
temperature-controlled room using high-resolution ultrasound
(UNEXEF18G, UNEX Corporation, Nagoya, Japan). Flow-mediated
dilatation was calculated as the percentage of change in diameter
from the baseline value before cuff release to the peak value after
cuff release: %Flow-mediated dilatation= [(vessel diameter reac-
tive hyperemia−vessel diameter at rest)×100]/vessel diameter at
rest [22].
Cardio-ankle vascular index
Cardio-ankle vascular index (CAVI) as an index of arterial stiff-
ness was measured blindly using a Vasera VS-1000 device (Fukuda
Denshi, Tokyo, Japan) as previously reported [23], while the sub-
jects were awake between 08:00h and 12:00h. CAVI reﬂects the
stiffness of the aorta, femoral arteries, and tibial arteries as a whole
[23].
Signal averaged ECG
The signal averaged ECGwas recorded using bipolar orthogonal
leadsaspreviously reported [15]. Recordingswereperformed in the
supine position with CardioStar FCP-7541 (Fukuda Denshi). Three
parameterswere computed: RMS40, the root-mean-square voltage
of the signals in the last 40ms; LAS40, the duration of the low-
amplitude signal after the voltage decreased to less than40V; and
fQRS, ﬁltered QRS-duration. Late potential positive was deﬁned as
two of three parameters (RMS40, LAS40, fQRS) showing positive.
Echocardiography
Echocardiography was performed blindly by an experienced
echocardiographer using the standard techniques. Echocardiog-
raphic parameters investigated included interventricular septum
thickness, left ventricular (LV) dimension, posterior wall thick-
ness, LV volume, LV ejection fraction (LVEF), left atrial volume,
and the ratio of early transmitral ﬂow velocity to mitral annu-
lar velocity (mitral valve E/E′), inferior vena cava diameter, peak
systolic pulmonary artery pressure (SPAP), right atrial diameter,
right ventricular (RV) diameter, RV area, RV fractional area change
(RV-FAC), Doppler-derived tricuspid lateral annular systolic veloc-
ity (tricuspid valve S′), etc. [24]. The LVEF was calculated using a
modiﬁcation of the Simpson’s method. Mitral valve E/E′ was calcu-
lated by transmitral Doppler ﬂowand tissueDoppler imaging. SPAP
was calculated by adding the right atrial pressure (estimated by the
diameter and collapsibility of the inferior vena cava) to the systolic
trans tricuspid pressure gradient [12,24]. The RV-FAC, deﬁned as
(end diastolic area-end systolic area)/end diastolic area×100, is
a measure of RV systolic function [24]. All recordings were per-
formed on ultrasound systems (ACUSON Sequoia, SiemensMedical
Solutions USA, Inc., Mountain View, CA, USA).
Statistical analysis
Normally distributed data are presented as mean± SD, non-
normally distributed data are presented as median (interquartile
range), and categorical variables are expressed as numbers and
percentages. We used the one-way repeated-measures analysis of
variance (ANOVA) followed by Tukey’s post hoc test. Non-normally
distributed datawere analyzed by the Kruskal–Wallis test. The chi-
square test was used for categorical variables among the three
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roups. Kaplan–Meier method was used for presenting the event-
ree rate and the log-rank test was used for initial comparisons.
nivariate andmultivariate Cox proportional hazard analyseswere
sed to analyze predictors of events with adjusting confounding
actors. To prepare for potential confounding, we introduced the
ollowing factors, known to affect the risk of worsening HF, cardiac
eath, or all-cause mortality in HF patients: age, gender, pres-
nce of atrial ﬁbrillation, chronic kidney disease, anemia, COPD
GOLD stage I, GOLD stage II), B-type natriuretic peptide (BNP), tro-
onin T, LVEF, RV-FAC, SPAP, CAVI, angiotensin-converting enzyme
ACE) inhibitor/angiotensin II receptor blocker (ARB) therapy, and
-blocker therapy. Univariate parameters with a p-value of <0.10
ere included in the multivariate analysis. A value of p<0.05 was
onsidered signiﬁcant for all comparisons. All analyses were per-
ormed using a statistical software package (SPSS ver. 21.0, IBM,
rmonk, NY, USA).
esults
In our hospitalized HF patients, the prevalence of COPD was
8.0% (106/378). There were 82 COPD patients with GOLD stage
and 24 patients with GOLD stage II. There were no patients with
OLD stage III or IV. As shown in Tables 1–3, comparisons of clin-
cal features revealed that HF patients with GOLD II rather than
on-COPD: (1) were of older age, (2) had a greater presence of ane-
ia, (3) were less likely to be receiving -blocker therapy, (4) had
igher troponin T levels, (5) lower vital capacity, %vital capacity
nd peak expiratory ﬂow, and (6) higher CAVI. In contrast, BNP,
GFR, C-reactive protein, presence of late potential positive, LV and
eft atrial volume, LV systolic function (LVEF), LV diastolic function
mitral valve E/A, mitral valve E/E′), RV and right atrial diameters
nd areas, SPAP, RV systolic function (RV-FAC, tricuspid valve S′),
nd RV diastolic function (tricuspid valve E/A, tricuspid valve E/E′)
able 1
omparisons of clinical features of HF patients with or without COPD.
Non-COPD (n=272)
Age (years) 64.1±14.8
Male gender (n, %) 169 (62.1)
Body mass index (kg/cm2) 23.1±4.0
Systolic blood pressure (mmHg) 120.2±18.7
Diastolic blood pressure (mmHg) 73.6±11.7
Heart rate (bpm) 70.1±14.6
Ischemic etiology (n, %) 98 (36.0)
Co-morbidity
Hypertension (n, %) 201 (73.9)
Diabetes (n, %) 87 (32.0)
Dyslipidemia (n, %) 203 (74.6)
Atrial ﬁbrillation (n, %) 100 (36.8)
Chronic kidney disease (n, %) 161 (59.2)
Anemia (n, %) 131 (48.2)
Smoking (n, %) 94 (34.6)
Medications
ACE inhibitors/ARB (n, %) 237 (87.1)
-Blockers (n, %) 216 (79.4)
Laboratory data
PO2 69.9±28.8
PCO2 34.7±20.1
White blood cell (/l) 6.19±3.64
Hemoglobin (g/dl) 12.5±2.4
BNP (pg/ml)a 352.7 (581.3)
eGFR (ml/min/1.73 cm2) 54.3±26.0
C-reactive protein (mg/dl)a 0.21 (0.57)
Troponin T (ng/ml)a 0.020 (0.021)
OPD, chronic obstructive pulmonary disease; ACE, angiotensin-converting enzyme; ARB
lomerular ﬁltration rate.
a Data are presented as median (interquartile range).
* p<0.05 vs. non-COPD.
** p<0.01 vs. non-COPD.iology 64 (2014) 256–264
did not differ between the three groups. In summary, HF patients
withmoderate COPD rather than those without COPD not only had
respiratoryobstructivedisorder, but also restrictivedisorder, latent
myocardial damage, and greater arterial stiffness.
During the follow-upperiod (mean495days), therewere36 car-
diac deaths, 27 non-cardiac deaths, and 96 re-hospitalizations from
worseningHF.Details of cardiacandnon-cardiacdeathswereas fol-
lows: HF (n=29), ventricular ﬁbrillation (n=7), respiratory failure
and/or pneumonia (n=10), cancer (n=9), sepsis (n=5), digestive
hemorrhage (n=2), and renal failure (n=1). As shown in Fig. 1,
while there was no signiﬁcant difference in event-free rates of all-
cardiac events (A) among the three groups, the event-free rates of
cardiac death (B), non-cardiac death (C), and all-cause mortality
(D) were signiﬁcantly lower in the GOLD II (moderate COPD) group
than in the other groups.
To examine prognostic factors in HF patients, the Cox pro-
portional hazard model was used (Tables 4–7). With respect to
all cardiac events (cardiac death and re-hospitalization) in HF
patients (Table 4), atrial ﬁbrillation [hazard ratio (HR) 1.382,
95% CI 1.008–2.316, p=0.041], chronic kidney disease (HR 3.472,
95% CI 2.027–5.866, p=0.003), GOLD stage II (HR 2.005, 95% CI
1.078–4.271, p=0.036), and LVEF (HR 0.835, 95% CI 0.472–0.976,
p=0.021) were independent predictors. With respect to cardiac
death in HF patients (Table 5), chronic kidney disease (HR 2.315,
95% CI 1.042–5.026, p=0.042), GOLD stage II (HR 3.014, 95% CI
1.106–8.632, p=0.038), RV-FAC (HR 0.577, 95% CI 0.261–0.945,
p=0.047), and SPAP (HR 1.374, 95% CI 1.063–1.752, p=0.021) were
independent predictors. With respect to non-cardiac death in HF
patients (Table 6), age (HR 1.067, 95% CI 1.023–1.114, p=0.003),
anemia (HR 2.689, 95% CI 1.064–6.794, p=0.037), and GOLD stage
II (HR 2.645, 95% CI 1.012–7.632, p=0.036) were independent
predictors. With respect to all-cause mortality in HF patients
(Table 7), chronic kidney disease (HR 1.953, 95% CI 1.084–2.827,
GOLD I (n=82) GOLD II (n=24) p value
73.8±10.7** 76.0±7.9** <0.001
61 (74.4) 16 (66.7) 0.123
23.1±3.9 22.2±3.7 0.567
119.9±20.2 113.9±18.6 0.498
71.7±12.2 66.5±11.5 0.078
71.7±12.2 66.5±11.5 0.622
32 (39.0) 8 (33.3) 0.838
64 (78.0) 15 (62.5) 0.308
32 (39.0) 11 (45.8) 0.238
51 (62.2) 16 (66.7) 0.086
41 (50.0) 10 (41.7) 0.102
50 (61.0) 14 (58.3) 0.952
51 (62.2) 16 (66.7) 0.029
35 (42.7) 11 (45.8) 0.268
71 (86.6) 23 (95.8) 0.444
57 (69.5) 14 (58.3) 0.014
63.2±28.2 59.5±27.3 0.399
36.5±17.5 43.2±15.7 0.349
5.85±3.19 6.33±3.13 0.728
11.9±2.3 11.6±3.2 0.156
290.9 (515.6) 409.8 (542.2) 0.807
53.0±21.9 50.7±19.8 0.853
0.32 (0.95) 0.65 (0.84) 0.121
0.025 (0.022) 0.033 (0.020)* 0.009
, angiotensin II receptor blocker; BNP, B-type natriuretic peptide; eGFR, estimated
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Table 2
Comparisons of pulmonary function test, vascular function, and signal averaged ECG.
Non-COPD (n=272) GOLD I (n=82) GOLD II (n=24) p value
Pulmonary function test
FEV1 (%) 81.0±6.5 65.6±6.6** 51.6±6.9**,†† <0.001
%FEV1 (%) 106.4±13.1 96.8±12.1** 68.1±7.7**,†† <0.001
Vital capacity (L) 2.76±0.85 2.48±0.90* 2.28±0.81* 0.006
%Vital capacity (%) 88.0±18.6 81.4±20.4* 76.7±20.6* 0.003
Peak expiratory ﬂow (L/s) 5.08±2.06 4.14±1.82** 2.67±1.49**,†† <0.001
Vascular function
Flow-mediated dilatation (%) 4.35±2.88 3.81±2.59 4.02±2.01 0.820
CAVI 8.29±2.01 8.86±3.27 8.99±2.23* 0.032
Signal averaged ECG
Late potential positive (n, %) 37 (13.6) 16 (19.5) 5 (20.8) 0.319
ECG, electrocardiogram; FEV1 (%), forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC); CAVI, cardio-ankle vascular index.
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r* p<0.05 vs. non-COPD.
** p<0.01 vs. non-COPD.
†† p<0.01 vs. GOLD I.
= 0.038), anemia (HR 2.106, 95% CI 1.238–3.754, p=0.027), GOLD
tage II (HR 2.625, 95% CI 1.148–5.628, p=0.015), troponin T (HR
.256, 95% CI 1.035–1.973, p=0.034), SPAP (HR 1.298, 95% CI
.008–2.067, p=0.033), ACE inhibitors/ARB therapy (HR 0.763, 95%
I 0.424–0.952, p=0.037), and -blocker therapy (HR 0.683 95% CI
.462–0.973, p=0.042) were independent predictors. In summary,
oderate COPD (GOLD II)was an independent predictor of not only
ardiac death but also non-cardiac death and all-cause mortality
n HF patients. Furthermore, RV-FAC and SPAP were independent
redictors of cardiac death, regardless of the presence of COPD.
Next, we examined the effects of -blocker therapy in GOLD
I patients, since Cox proportional hazard analysis demonstrated
hat -blocker therapy was an independent predictor of all-
ause mortality in HF patients including mild to moderate COPD
Table 7). In Table 8, we compared background characteris-
ics between patients in GOLD II with and without -blockers.
here were no signiﬁcant differences in background characteris-
ics between the two groups. As shown in Fig. 2, Kaplan–Meier
able 3
omparisons of echocardiographic data.
Non-COPD (n=272)
Interventricular septum thickness (mm) 10.9 ± 2.7
Left ventricular end-diastolic dimension (mm) 52.6 ± 10.3
Left ventricular end-systolic dimension (mm) 38.5 ± 12.6
Posterior wall thickness (mm) 11.0 ± 2.8
Left ventricular end-diastolic volume (ml) 121.0 ± 62.2
Left ventricular end-systolic volume (ml) 65.5 ± 44.7
LVEF (%) 48.9 ± 15.2
Left atrial volume (ml) 87.3 ± 58.8
Mitral valve E/A 1.18 ± 0.73
Mitral valve early wave deceleration time (ms) 219.8 ± 113.3
Mitral valve E′ (cm/s) 6.29 ± 2.65
Mitral valve E/E′ 15.6 ± 9.1
Inferior vena cava diameter (mm) 15.4 ± 5.2
SPAP (mmHg) 35.1 ± 15.1
Right atrial diameter-major (mm) 52.5 ± 12.5
Right atrial diameter-minor (mm) 37.8 ± 10.3
Right atrial end systolic area (cm2) 19.6 ± 10.5
Right ventricular diameter-long (mm) 68.1 ± 14.2
Right ventricular diameter-base (mm) 34.9 ± 9.2
Right ventricular area-diastolic (ml) 17.0 ± 6.5
Right ventricular area-systolic (ml) 10.2 ± 4.6
RV-FAC (%) 43.5 ± 15.9
Tricuspid valve S′ (cm/s) 9.88 ± 4.33
Tricuspid valve E/A 1.08 ± 0.37
Tricuspid valve E/E′ 5.83 ± 4.50
VEF, left ventricular ejection fraction; Mitral valve E/A, ratio of early to late transmitral
atio of the peak transmitral velocity during early diastole to the peak mitral valve annu
ricuspid valve S′ , Doppler-derived tricuspid lateral annular systolic velocity; tricuspid v
atio of the peak transtricuspid velocity during early diastole to the peak tricuspid valve aanalysis demonstrated that event-free survival rate tended to
be higher in GOLD II with -blockers than in GOLD II with
out -blockers (p=0.057).
Discussion
To the best of our knowledge, the present study is the ﬁrst to
show clinical features of HF patients according to precise GOLD
stage, from a view point of comprehensive cardiovascular function
and detailed prognosis for cardiac and non-cardiac events. Major
ﬁndings of this study were (1) the prevalence of COPD in hospi-
talized HF patients was 28.0%, (2) HF patients with GOLD stage II
group, as compared to non-COPD group, had (a) higher troponin T;
(b) greater CAVI; (c) similar cardiac systolic and diastolic function
of the right and left ventricle; (d) similar renal function; and (e)
higher cardiac and non-cardiac mortality, and (3) -blocker ther-
apywas an independent factor for all-causemortality inHFpatients
including mild to moderate COPD.
GOLD I (n=82) GOLD II (n=24) p value
11.0 ± 2.6 10.6 ± 2.7 0.805
53.0 ± 11.1 49.5 ± 8.7 0.362
39.2 ± 12.7 37.4 ± 10.6 0.833
11.5 ± 3.1 10.6 ± 2.5 0.379
115.0 ± 60.7 98.7 ± 46.9 0.236
61.9 ± 43.5 53.8 ± 32.5 0.444
49.3 ± 13.8 47.9 ± 18.1 0.937
97.5 ± 51.4 88.0 ± 43.8 0.484
1.17 ± 0.65 0.92 ± 0.38 0.268
208.3 ± 95.4 195.8 ± 90.0 0.550
5.96 ± 2.95 5.75 ± 1.97 0.574
17.9 ± 8.0 16.6 ± 9.1 0.268
16.1 ± 6.1 14.8 ± 4.9 0.515
40.9 ± 15.3 39.1 ± 22.5 0.313
49.3 ± 12.9 62.1 ± 16.9 0.078
37.3 ± 15.5 43.9 ± 9.7 0.155
23.1 ± 11.4 21.2 ± 10.5 0.256
69.9 ± 17.8 64.3 ± 13.7 0.536
35.9 ± 10.4 35.7 ± 15.0 0.862
18.6 ± 7.2 17.9 ± 9.1 0.553
11.5 ± 5.0 9.9 ± 5.9 0.447
43.3 ± 19.2 45.0 ± 9.5 0.947
9.98 ± 4.34 9.18 ± 4.28 0.925
1.08 ± 0.53 0.93 ± 0.41 0.686
5.54 ± 3.94 6.23 ± 3.75 0.947
peak ﬂow velocities; SPAP, systolic pulmonary artery pressure; Mitral valve E/E′ ,
lar velocity during early diastole; RV-FAC, right ventricular fractional area change;
alve E/A, ratio of early to late transmitral peak ﬂow velocities; tricuspid valve E/E′ ,
nnular velocity during early diastole.
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long GOLD II, GOLD I, and non-COPD groups. COPD, chronic obstructive pulmonary
mpacts of COPD on cardiovascular function
COPD increases the risk of cardiovascular disease by hypoxia,
ystemic inﬂammation, and oxidative stress [1]. Cardiovascular
isease becomes more prevalent with increasing COPD severity,
ith a higher incidence of atherosclerosis [25], arrhythmia [26,27],
schemic heart disease, and HF [1,28]. In patients without HF,
able 4
ox proportional hazard model of all-cardiac events in heart failure.
Risk factor Univariate
HR 95% CI
Age 1.010 0.996–1.023
Male 1.200 0.803–1.792
Atrial ﬁbrillation 1.428 0.981–2.077
Chronic kidney disease 3.776 2.324–6.137
Anemia 1.490 1.020–2.176
COPD
Non-COPD (reference) 1
GOLD I 1.342 0.898–2.004
GOLD II 2.070 1.044–4.101
BNP (+1SD increase) 1.286 0.926–2.290
Troponin T (+1SD increase) 1.374 1.008–2.365
LVEF (+1SD increase) 0.776 0.635–0.956
RV-FAC (+1SD increase) 0.803 0.557–1.144
SPAP (+1SD increase) 1.128 0.941–1.369
CAVI (+1SD increase) 1.072 0.859–1.201
ACE inhibitor/ARB therapy 0.860 0.506–1.462
-Blocker therapy 0.736 0.357–1.125
hese factors are adjusted for gender and age. HR, hazard ratio; CI, conﬁdence interval
VEF, left ventricular ejection fraction; RV-FAC, right ventricular fractional area change;
ngiotensin-converting enzyme; ARB, angiotensin II receptor blocker.eart failure); (B) cardiac death; (C) non-cardiac death; and (D) all-cause mortality
se.
therewere no signiﬁcant differences between COPD andnon-COPD
with regard to left and right ventricular wall thickness, LVEF, or
SPAP, but there was subclinical diastolic dysfunction evidenced
by myocardial performance index and strain rate [29]. Severe
COPD is accompanied by airway obstruction, hypoxia, ventilation-
perfusion mismatch, pulmonary vasoconstriction, oxidative stress,
endothelial dysfunction, and inﬂammation, and thus may result
Multivariate
p value HR 95% CI p value
0.170
0.369
0.063 1.382 1.008–2.316 0.041
<0.001 3.472 2.027–5.866 0.003
0.039 1.438 0.982–2.351 0.063
0.151
0.037 2.005 1.078–4.271 0.036
0.205
0.011 1.125 0.938–1.829 0.064
0.019 0.835 0.472–0.976 0.021
0.215
0.178
0.229
0.578
0.138
; COPD, chronic obstructive pulmonary disease; BNP, B-type natriuretic peptide;
SPAP, systolic pulmonary artery pressure; CAVI, cardio-ankle vascular index, ACE,
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Table 5
Cox proportional hazard model of cardiac death in heart failure.
Risk factor Univariate Multivariate
HR 95% CI p value HR 95% CI p value
Age 1.004 0.981–1.027 0.738
Male 1.292 0.636–2.627 0.479
Atrial ﬁbrillation 1.096 0.565–2.126 0.787
Chronic kidney disease 2.755 1.206–6.290 0.008 2.315 1.042–5.026 0.042
Anemia 2.099 1.049–4.199 0.031 1.764 0.928–3.571 0.075
COPD
Non-COPD (reference) 1
GOLD I 1.004 0.484–2.082 0.992
GOLD II 3.229 1.132–9.210 0.028 3.014 1.106–8.632 0.038
BNP (+1SD increase) 1.999 1.072–2.826 0.055 1.274 0.080–2.264 0.273
Troponin T (+1SD increase) 1.829 1.038–2.591 0.045 1.438 0.946–2.024 0.071
LVEF (+1SD increase) 0.753 0.496–1.143 0.178
RV-FAC (+1SD increase) 0.358 0.112–1.162 0.060 0.577 0.261–0.945 0.047
SPAP (+1SD increase) 1.722 1.252–2.089 <0.001 1.374 1.063–1.752 0.021
CAVI (+1SD increase) 1.174 0.953–1.446 0.132
ACE inhibitor/ARB therapy 0.404 0.189–0.863 0.019 0.653 0.335–1.114 0.076
-Blocker therapy 0.253 0.119–0.538 <0.001 0.831 0.338–1.128 0.087
H se; BN
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n pulmonary vascular remodeling, right ventricular hypertrophy
30], RV diastolic [30] and systolic dysfunction, and pulmonary
ypertension [31,32]. COPD is reportedly associated with impair-
ent of LVﬁlling, reduced stroke volume, and lower cardiac output,
ithout changes in the LVEF [6,7,33]. Conversely, LV dysfunction
as reported in COPD patients [34]. Recently, it has been reported
hat stable COPDwithoutHF [35] and acute exacerbationCOPD [36]
reassociatedwithelevationof cardiac troponinT.Ourpresentdata
ere concordant with the previous ﬁndings that moderate COPD
oncomitant with HF had features of greater myocardial damage,
reater arterial stiffness, along with similar systolic and diastolic
unction of RV and LV.
mpact of COPD on prognosis of HFOur present data were concordant with previous reports show-
ng that COPD was an independent predictor of all-cause mortality
6–8]. Staszewsky et al. [6] reported that COPD is a weak predictor
able 6
ox proportional hazard model of non-cardiac death in heart failure.
Risk factor Univariate
HR 95% CI
Age 1.082 1.038–1.127
Male 0.505 0.237–1.075
Atrial ﬁbrillation 1.671 0.785–3.556
Chronic kidney disease 1.626 0.712–3.716
Anemia 3.583 1.446–8.880
COPD
Non-COPD (reference) 1
GOLD I 2.390 1.123–5.084
GOLD II 5.002 1.884–13.276
BNP (+1SD increase) 1.000 1.000–1.000
Troponin T (+1SD increase) 1.145 0.873–1.572
LVEF (+1SD increase) 1.308 0.775–1.927
RV-FAC (+1SD increase) 0.935 0.288–2.992
SPAP (+1SD increase) 1.332 0.956–1.756
CAVI (+1SD increase) 1.027 0.754–1.399
ACE inhibitor/ARB therapy 1.226 0.339–3.745
-Blocker therapy 0.923 0.420–2.028
R, hazard ratio; CI, conﬁdence interval; COPD, chronic obstructive pulmonary disease; BN
entricular fractional area change; SPAP, systolic pulmonary artery pressure; CAVI, card
eceptor blocker.P, B-type natriuretic peptide; LVEF, left ventricular ejection fraction; RV-FAC, right
io-ankle vascular index, ACE, angiotensin-converting enzyme; ARB, angiotensin II
of all-cause mortality but a strong predictor of non-cardiovascular
mortality in HF patients (HR 2.50, 95% CI 1.58–3.96) when tak-
ing -blockers (36.7% in non-COPD and 22.3% in COPD). In their
study, plasma norepinephrine, plasma renin activity, neutrophils,
C-reactive protein, and troponin were consistently higher in HF
patients with COPD [6]. Kwon et al. [5] reported that severe COPD
was independently associated with composite cardiovascular and
pulmonary event-free survival (GOLD III vs. I, HR 3.20, 95% CI
1.33–7.68) when taking -blockers (22%). Mentz et al. [37] indi-
cated that COPDwas associatedwith increased co-morbidities, less
use of evidence-basedHFmedications, longer hospitalizations, and
increased in-hospital non-cardiovascular mortality (OR 1.65, 95%
CI 1.12–2.41). However, there was a similar post-discharge 60-day
mortality. Our study differs from previous studies [2,5–8,37,38] in
many ways: for instance, we presented comprehensive cardiovas-
cular function and detailed cardiovascular and non-cardiovascular
events; our HF patients underwent precise COPD diagnosis by
spirometry with GOLD I or II and took more -blockers than
Multivariate
p value HR 95% CI p value
<0.001 1.067 1.023–1.114 0.003
0.116
0.183
0.249
0.006 2.689 1.064–6.794 0.037
0.024 1.373 0.623–3.022 0.152
0.001 2.645 1.012–7.632 0.036
0.272
0.105
0.391
0.901
0.094 1.118 0.835–1.843 0.136
0.865
0.846
0.844
P, B-type natriuretic peptide; LVEF, left ventricular ejection fraction; RV-FAC, right
io-ankle vascular index, ACE, angiotensin-converting enzyme; ARB, angiotensin II
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Table 7
Cox proportional hazard model of all-cause mortality in heart failure.
Risk factor Univariate Multivariate
HR 95% CI p value HR 95% CI p value
Age 1.027 1.006–1.048 0.011 1.006 0.968–1.022 0.373
Male 0.883 0.529–1.472 0.632
Atrial ﬁbrillation 1.269 0.770–2.094 0.352
Chronic kidney disease 2.107 1.178–3.768 0.012 1.953 1.084–2.827 0.038
Anemia 2.542 1.469–4.401 0.001 2.106 1.238–3.754 0.027
COPD
Non-COPD (reference) 1
GOLD I 1.428 0.849–2.404 0.179
GOLD II 3.560 1.685–7.520 0.001 2.625 1.148–5.628 0.015
BNP (+1SD increase) 1.110 1.010–1.231 0.045 1.000 1.000–1.000 0.098
Troponin T (+1SD increase) 1.372 1.008–1.836 0.002 1.256 1.035–1.973 0.034
LVEF (+1SD increase) 0.942 0.675–1.248 0.564
RV-FAC (+1SD increase) 0.517 0.199–1.330 0.171
SPAP (+1SD increase) 1.503 1.197–1.756 <0.001 1.298 1.008–2.067 0.033
CAVI (+1SD increase) 1.125 0.945–1.338 0.172
ACE inhibitor/ARB therapy 0.572 0.304–1.075 0.083 0.763 0.424–0.952 0.037
-Blocker therapy 0.521 0.308–0.883 0.015 0.683 0.462–0.973 0.042
H se; BN
v I, card
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entricular fractional area change; SPAP, systolic pulmonary artery pressure; CAV
eceptor blocker.
n previous studies [5–8,38] (79.4% in non-COPD and 67.9% in
OPD).
It has been reported that elevated circulating levels of troponins
ere correlatedwith severity of disease andwith adverse all-cause
ortality in HF patients [14,39]. Underlying mechanisms for the
able 8
ackground characteristics between patients in COPD grade II with and without -blocke
GOLD II with -blockers (n=14)
Age (years) 74.0±8.6
Male gender (n, %) 11 (78.6)
Body mass index (kg/cm2) 21.7±2.5
Systolic blood pressure (mmHg) 114.0±19.4
Diastolic blood pressure (mmHg) 66.2±13.0
Heart rate (bpm) 65.7±9.2
Ischemic etiology (n, %) 4 (28.6)
Co-morbidity
Hypertension (n, %) 10 (71.4)
Diabetes (n, %) 6 (42.9)
Dyslipidemia (n, %) 9 (64.3)
Atrial ﬁbrillation (n, %) 4 (28.6)
Chronic kidney disease (n, %) 8 (57.1)
Anemia (n, %) 9 (64.3)
Smoking (n, %) 7 (50.0)
Medications
ACE inhibitors/ARB (n, %) 13 (92.9)
Data
PO2 61.4±16.4
PCO2 42.8±13.5
White blood cell (/l) 6.51±3.07
Hemoglobin (g/dl) 12.4±2.7
BNP (pg/ml)a 488.5 (687)
eGFR (ml/min/1.73 cm2) 54.1±20.0
C-reactive protein (mg/dl)a 0.66 (0.9)
Troponin T (ng/ml)a 0.035 (0.021)
FEV1 (%) 53.4±6.4
%FEV1 (%) 69.8±6.6
Vital capacity (L) 2.45±0.92
%Vital capacity (%) 80.6±23.3
LVEF (%) 40.9±17.4
RV-FAC (%) 43.7±11.1
SPAP (mmHg) 41.9±26.6
R, hazard ratio; CI, conﬁdence interval; COPD, chronic obstructive pulmonary disease;
eft ventricular ejection fraction; RV-FAC, right ventricular fractional area change; SPAP
ngiotensin II receptor blocker; FEV1 (%), forced expiratory volume in 1 s (FEV1)/forced vi
a Data are presented as median (interquartile range).P, B-type natriuretic peptide; LVEF, left ventricular ejection fraction; RV-FAC, right
io-ankle vascular index, ACE, angiotensin-converting enzyme; ARB, angiotensin II
association between increases of troponins and all-causemortality
in HF patients remain unclear, however, it may be due to car-
diac stress including inﬂammation, sympathetic nervous activity,
hypoxia, andothers. Inﬂammatorymediators fromCOPDhavebeen
proposed to exist in HF [40]. Moreover, signiﬁcant associations
rs.
GOLD II without -blockers (n=10) p value
78.9±6.1 0.137
5 (50.0) 0.153
23.0±5.3 0.427
113.7±19.0 0.979
67.7±2.1 0.852
70.1±12.5 0.498
4 (40.0) 0.439
5 (50.0) 0.260
5 (50.0) 0.527
7 (70.0) 0.561
6 (60.0) 0.132
6 (60.0) 0.611
7 (70.0) 0.561
4 (40.0) 0.473
10 (100.0) 0.583
58.5±19.1 0.263
44.8±16.7 0.737
6.17±3.39 0.837
10.7±3.8 0.278
398.7 (320) 0.719
47.8±20.7 0.499
0.48 (0.8) 0.321
0.032 (0.020) 0.917
48.3±7.0 0.114
65.8±8.9 0.214
1.98±0.47 0.233
69.6±13.0 0.265
55.2±12.3 0.072
47.7±5.4 0.519
34.7±14.1 0.631
BNP, B-type natriuretic peptide; eGFR, estimated glomerular ﬁltration rate; LVEF,
, systolic pulmonary artery pressure; ACE, angiotensin-converting enzyme; ARB,
tal capacity (FVC).
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[ig. 2. Kaplan–Meier analysis for event-free survival between GOLD II with
-blockers and GOLD II without -blockers.
etween troponin and inﬂammatory markers have been reported
41]. In our present study, troponin T was signiﬁcantly higher in
OLD II than in non-COPD group, and troponin T was an indepen-
entpredictor of all-causemortality inHFpatients.Higher troponin
might affect worse outcome in HF patients with moderate COPD.
Right ventricular systolic function [11,12] and pulmonary atrial
ressure [12,13] are the reported predictors of cardiac events. SPAP
as reportedly an independent predictor of adverse prognosis not
nly inHFpatients [12,13], but also inCOPDpatients [42]. Ghio et al.
12] found that pulmonary hypertension and RV dysfunction were
ssociated with adverse cardiac events. However, patients with
OPDwere excluded, spirometrywas not routinely performed, and
nly cardiac events were examined in their study unlike ours. In
ur investigation, RV-FAC and SPAP were independent predictors
f cardiac death in HF patients, regardless of the presence of COPD.
tudy limitations
Several limitations remain in the present study. First, this was a
rospective observational study including only HF patients who
nderwent spirometry. Second, we did not use a bronchodila-
or when spirometry was performed. Hence, we were unable
o completely exclude bronchial asthma. However, making a
erfect differentiating diagnosis between COPD and asthma is
irtually impossible in HF patients. Third, only HF patients with
ild–moderate COPD (GOLD I or II)were included in our study, and
hus the impact of severe–very severeCOPD (GOLD III or IV)wasnot
ufﬁciently elucidated. Fourth, we evaluated RV function and SPAP
sing echocardiography, rather than using right heart catheter-
zation, cardiac magnetic resonance imaging, and radionuclide
entriculography. However, these are not routinely performed in
F patients. Fifth, the number of subjects was relatively small
ecause this study was performed in a single institution. Hence,
urther studies with a larger population are needed. However, it is
mportant to recall that diagnoses of HF and COPD were accurately
adebyourexperiencedcardiologistsusing theFraminghamcrite-
ia and spirometry.
onclusions
Moderate COPD (GOLD stage II) was an independent predictor
f not only cardiac death but also non-cardiac death and all-cause
ortality inHFpatients.ModerateCOPDpatientswithconcomitant
F had (1) not only obstructive, but also restrictive respiratory dys-
unction, (2) myocardial damage, (3) greater arterial stiffness, and
4) similar systolic anddiastolic function of the right and left ventri-
le. These mechanisms may affect the prognosis of HF with COPD.
urthermore, -blocker therapy was an independent factor for all-
ause mortality in HF patients including mild to moderate COPD.
hese ﬁndings provide an important background for prospectively
[iology 64 (2014) 256–264 263
assessing the comparative yield of strategies designed for optimi-
zing treatment in HF patients with and without COPD.
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